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Background: Accumulation of β-amyloid (Aβ) and cholinergic deficiency are two prominent features of Alzheimer’s
disease (AD). To understand how Aβ-induced dysfunction of the nicotinic system may contribute to cognitive
impairment in AD, we examined the effect of Aβ on nicotinic regulation of synaptic transmission and neuronal
excitability in prefrontal cortex (PFC), a brain region critical for cognitive processes.
Results: We found that activation of nicotinic acetylcholine receptors (nAChRs) with nicotine increased the
inhibitory postsynaptic currents recorded in PFC pyramidal neurons, which was associated with the
nicotine-induced increase in the excitability of PFC layer I GABAergic interneurons. Both effects of nicotine were
disrupted by Aβ. However, Aβ did not impair nicotinic regulation of excitatory neurotransmission in PFC
interneurons. The nicotinic effect on synaptic inhibition was also lost in transgenic mice with five familial
Alzheimer’s disease mutations. Inhibiting PKC attenuated nicotinic regulation of inhibitory, but not excitatory,
neurotransmission.
Conclusions: Our study suggests that Aβ selectively impairs nicotinic regulation of inhibitory inputs to PFC
pyramidal neurons, which might be due to its interference with PKC activation. Thus, in the PFC circuits of AD, the
balance between inhibition and excitation under the control of nAChRs may be disturbed by Aβ.
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Aβ plays a critical role in the pathogenesis of Alzhei-
mer’s disease (AD) [1-4]. Earlier studies show that Aβ
can cause cell death in cultured neurons [5] by inducing
oxidative stress and disrupting intracellular calcium
homeostasis [6]. Recent evidence suggests that the cog-
nitive deficit and memory loss in early stages of AD are
due to synaptic failure [7] and functional changes in the
activity of neuronal network [8]. However, the role of Aβ
in synaptic dysfunction in AD is far from clear.
In addition to Aβ accumulation, another hallmark of
AD is a selective loss of cholinergic neurons in basal
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reproduction in any medium, provided the orreceptors (nAChRs) in the hippocampus and cortex
[10,11]. Neuronal nAChR is a pentameric structure
formed from α- and β- subunits (α2-α10, β2-β4).
nAChRs are distributed in both presynaptic and postsy-
naptic sites [12,13], regulating transmitter release, synap-
tic response and neuronal excitability [14]. Animal
studies have found that nAChR activation improves
working memory [15,16], while nAChR antagonist,
mecamylamine, impairs attention accuracy or reaction
time [17,18]. Clinical drugs targeting nAChRs improve
symptoms in AD patients [19].
It has been suggested that nAChRs are involved in
regulating the integrated circuit activity between inter-
neurons and projection neurons [20,21]. We hypothesize
that Aβ may interrupt nicotinic regulation of inhibitory/
excitatory balance at cortical circuits, thus contributing
to the loss of cognition and memory in AD. To test this,
we examined the effect of nicotine on inhibitory inputstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to cortical interneurons, as well as the potential impact
of Aβ on the regulatory effects of nAChRs.Results
Nicotine increases inhibitory neurotransmission in PFC
layer V pyramidal neurons through non-α7 nACh
receptors
We first assessed the effect of nAChR activation on in-
hibitory neurotransmission in layer V pyramidal neurons
in the prefrontal cortex (PFC). Nicotine (5 μM, [22,23])
was applied to the bath solution for 10 min. As shown
in Figure 1A-D, nicotine significantly increased sIPSC
amplitudes, as indicated by a rightward shift of their dis-
tribution. Moreover, nicotine significantly increased
sIPSC frequencies, as indicated by a leftward shift of the
distribution of inter-event intervals. The effect of nito-
nine on sIPSC was reversible. Note that sIPSC was com-
pletely blocked by bicuculline (10 μM), indicating its
mediation by GABAA receptors (Figure 1A). In the sam-
ple of cells we tested, nicotine increased sIPSC ampli-






























Figure 1 Nicotine enhanced sIPSC in PFC layer V pyramidal neurons.
distribution of sIPSC amplitude (B) and frequency (C) in the absence (contr
neuron. The blockade of sIPSC by bicuculline (10 μM) was also shown in A
increase of sIPSC amplitude and frequency by nicotine in the absence or p
or MLA (methyllycaconitine, 1 μM, an α7 nAChR antagonist). *: p < 0.05, **:To identify the possible receptor subtypes that mediate
the nicotinic effect, we applied nAChR antagonists to
PFC slices. As shown in Figure 1D, mecamylamine
(MEC, 10 μM), a non-α7 nAChR antagonist, largely
blocked the effect of nicotine on sIPSC amplitude (0.4 ±
1.6%, n = 5) and frequency (12.6 ± 4.1%, n = 5). In contrast,
in the presence of methyllycaconitine (MLA, 1 μM), an α7
nAChR antagonist, the effect of nicotinic on sIPSC was
not significantly changed (amplitude: 41.1 ± 6.9%, fre-
quency: 41.3 ± 3.8%, n = 6). It suggests that the nicotinic
effect on sIPSC in layer V PFC pyramidal neurons is
mediated by non-α7 nAChRs.Nicotine boosts the excitability of PFC layer I GABAergic
interneurons
To assess whether nicotinic enhancement of sIPSC is
due to nAChR-induced increase in the excitability of
PFC GABAergic interneurons, we examined the effect of
nicotine on action potential firing of interneurons in
PFC. Since layer I of neocortex contains exclusively
GABAergic interneurons with extensive axonal plexus
innervating neurons in deep layers [24-26], we focused






















































































A-D, Representative sIPSC traces (A) and cumulative plots of the
ol, wash) or presence of nicotine (5 μM) recorded in a PFC pyramidal
. Scale bars (A): 50 pA, 5s. D, Bar plot summary of the percentage
resence of MEC (mecamylamine, 10 μM, a non-α7 nAChR antagonist)
p < 0.005, ANOVA.
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increase in the spike number in the representative layer
I interneuron. We noticed that nicotine caused a signifi-
cant change in the resting potential in a portion of layer
I interneurons (6/15, ΔRm >5%, from −66.4 ± 3.5 mV
to −60.4 ± 3.4 mV), but not in others (9/15, ΔRm <5%,
from −68.7 ± 2.9 mV to −67.3 ± 3.0 mV). The Rm change
is similar to the nicotine-induced depolarization in some
hippocampal neurons [27]. So we divided these cells into
two groups before evaluating the effect of nicotine on the
firing rate. As shown in Figure 2B, nicotine significantly
increased the firing rate in both groups (ΔRm< 5%:
30.8 ± 6.7%, n = 9; ΔRm> 5%: 56.5 ± 16.4%, n = 6). In
the presence of nAChR antagonist MEC or MLA,
nicotine failed to change the resting potential in all
neurons we tested (MEC-treated cells: -60.9 ± 2.2 mV
to −60.4 ± 2.3 mV, n = 7; MLA-treated cells: -70.7 ± 1.8
to −69.7 ± 1.8 mV, n = 8). However, the nicotinic effect
on firing rate was significantly attenuated by MEC
(Figure 2B, 8.6 ± 3.3%, n = 7) or MLA (Figure 2B, 11.8 ±
4.4%, n = 8), suggesting that both non-α7 and α7 nAChRs







































Figure 2 Nicotine increased the excitability of PFC layer I GABAergic
current pulse in the absence (control) or presence of nicotine (5 μM) recor
B, Bar plot summary of the percentage increase of firing rate by nicotine in
(10 μM) or MLA (1 μM). Note that the effect of nicotine was calculated in t
by nicotine. *: p < 0.05, ANOVA.We also assessed whether nicotine affects the excit-
ability of deep layer neurons. We found that nicotine did
not cause a significant increase in the firing rate or rest-
ing potential of layer V fast-spiking interneurons (n = 5).
Nicotine also failed to show any significant effect on the
firing rate of layer V pyramidal neurons (n = 5).
Aβ attenuates the nicotinic effect on inhibitory
transmission in layer V cortical pyramidal neurons
Given the involvement of cholinergic hypofunction in
AD, we next examined whether Aβ could alter the nico-
tinic regulation of inhibitory synaptic transmission in
PFC pyramidal neurons. Aβ oligomers were generated as
we described and characterized before [28]. PFC slices
were incubated with Aβ oligomers (1 μM, [28-30]) for at
least 3 hours before recording. No significant difference
in basal sIPSC was observed after Aβ treatment (non-
treated: 35.2 ± 2.2 pA, 5.5 ± 1.1 Hz, n = 5; Aβ-treated:
36.8 ± 2.4 pA, 6.1 ± 1.0 Hz, n = 5). However, nicotine
failed to increase the amplitude or frequency of sIPSC in
Aβ-treated neurons. A representative example is shown
in Figure 3A-C. As summarized in Figure 3D, in layer V
pyramidal neurons pretreated with Aβ, the nicotine-Nicotine
+MEC +MLA
interneurons. A, Representative spikes elicited by a depolarizing
ded in a PFC layer I GABAergic interneuron. Scale bars: 50mV, 100ms.
layer I interneurons in the absence or presence the antagonist MEC
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Figure 3 Aβ diminished the nicotinic effect on sIPSC in PFC layer V pyramidal neurons. A-C, Representative sIPSC traces (A) and
cumulative plots of the distribution of sIPSC amplitude (B) and frequency (C) in the absence (control) or presence of nicotine (5 μM) recorded in
a PFC pyramidal neuron pre-incubated with Aβ oligomer (1 μM, 3 hours). Scale bars (A): 100pA, 15s. D, Bar plot summary of the percentage
change of sIPSC amplitude and frequency by nicotine in PFC pyramidal neurons with or without Aβ pretreatment. *: p < 0.05, **: p < 0.01, t-test.
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and frequency (2.03 ± 1.87%, n = 5) was significantly
smaller than that in non-treated control cells (amplitude:
41.2 ± 5.1%, frequency: 36.4 ± 7.8%, n = 4).
To confirm that the observed effect of Aβ also occurs
in vivo, we examined the transgenic mice with five famil-
ial Alzheimer’s disease mutations (5xFAD), which rapidly
recapitulate major features of AD amyloid pathology.
These mice start to accumulate intraneuronal Aβ42
at ~1.5 months of age within neuron soma and neurites
and amyloid deposition reaches a very large burden in
deep cortical layers [31]. As shown in Figure 4, nicotine
(5 μM) had almost no effect on sIPSC in 1.2-month-old
5xFAD mice (amplitude: 6.7 ± 1.8%, frequency: 7.1 ±
1.9%, n = 4), which was significantly different from the
enhancing effect of nicotine on sIPSC in age-matched
WT mice (amplitude: 24.2 ± 4.8%, frequency: 31.6 ±
5.2%, n = 6). These results suggest that Aβ impairs nico-
tinic regulation of inhibitory synaptic transmission in
PFC.
Aβ weakens the nicotinic effect on the excitability of PFC
layer I GABAergic interneurons
Since the nicotinic effect on sIPSC is due to its regula-
tion of the excitability of GABAergic interneurons, we
next examined whether Aβ also interferes with thenicotinic effect on action potential firing of layer I inter-
neurons. PFC slices were pretreated with Aβ oligomers
(1 μM) for at least 3 hours before recording. Nicotine
significantly increased the firing rate in non-treated con-
trol neurons, but not in Aβ-treated neurons. Representa-
tive examples are shown in Figure 5A and 5B. As
summarized in Figure 5C, in all the neurons pooled to-
gether (ΔRm> 5% and ΔRm< 5%), nicotine caused a sig-
nificantly smaller effect on the firing rate of Aβ-treated
interneurons (14.3 ± 8.5%, n = 9) than control cells (41.1 ±
7.5%, n = 15). In the subgroups with ΔRm< 5%, the effect
of nicotine on the firing rate in Aβ-treated cells (5.2 ±
2.4%, n = 7) was also significantly smaller than that in con-
trol cells (33.0 ± 6.2%, n = 9). It suggests that Aβ impairs
nicotinic regulation of GABAergic interneuron excitability
in PFC.
Aβ does not interfere with nicotinic regulation of
excitatory neurotransmission
Given the Aβ-induced impairment of nicotinic regulation
of inhibitory transmission and interneuron excitability, we
would like to know whether Aβ also impairs nicotinic
regulation of excitatory transmission. To do so, we exam-
ined the effect of nicotine on spontaneous EPSC (sEPSC)
in layer I interneurons treated with or without Aβ. As




































































































































































Figure 4 The nicotinic effect on sIPSC was lost in PFC pyramidal neurons from 5xFAD mice. A-F, Representative sIPSC traces (A, D) and
cumulative plots of the distribution of sIPSC amplitude (B, D) and frequency (C, E) in the absence (control, wash) or presence of nicotine (5 μM)
recorded in layer V PFC pyramidal neurons from WT vs. 5xFAD mice. Scale bars (A): 50 pA, 5 s. G, Bar plot summary of the percentage increase of
sIPSC amplitude and frequency by nicotine in WT vs. 5xFAD mice. *: p < 0.05, t-test.
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tude, in non-treated control cells. Similar effects were
observed in Aβ-treated cells (Figure 6D-F). Note that
sEPSC was completely blocked by DNQX (20 μM) plus
APV (40 μM), indicating its mediation by glutamate
receptors (Figure 6A). As summarized in Figure 6G, the
nicotine-induced enhancement of sEPSC frequency was
not significantly altered by Aβ treatment (non-treated:
103.3 ± 27.5%, n = 10; Aβ-treated: 83.0 ± 25.9%, n = 9).Why does Aβ differentially affect nicotinic regulation
of excitatory vs. inhibitory neurotransmission? One pos-
sibility is that distinct nAChR subtypes mediate the
nicotinic effect on sEPSC or sIPSC. To test this, we
applied specific nAChR antagonists. As shown in
Figure 6H, in cells treated with the non-α7 nAChR an-
tagonist MEC (10 μM), nicotine failed to increase sEPSC
frequency (2.6 ± 1.6%, n = 4). In contrast, the nicotinic































Figure 5 Aβ attenuated the nicotinic effect on layer I interneuron excitability. A, B, Representative spikes elicited by a depolarizing current
pulse in the absence (control) or presence of nicotine (5 μM) recorded in PFC layer I GABAergic interneurons without (A) or with Aβ pre-
treatment (B). Scale bars: 50mV, 100ms. C, Bar plot summary of the percentage increase of firing rate by nicotine in non-treated (−) and Aβ-
pretreated layer I interneurons. Note that the effect of nicotine was calculated in two different groups based on the change of resting potential
(ΔRm) by nicotine. *: p < 0.05, **: p < 0.01, ANOVA.
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MLA (1 μM). It suggests that non-α7 nAChRs play a
major role in mediating the nicotinic effect on excitatory
neurotransmission, which is similar to their major role
in mediating the nicotinic effect on inhibitory neuro-
transmission. Thus, the differential effects of Aβ on
nicotinic regulation of sIPSC and sEPSC can not be
explained by the nAChRs involved.
PKC is differentially involved in nicotinic regulation of
inhibitory vs. excitatory neurotransmission
Having excluded the possibility that nAChR subtypes
may contribute to the selective effect of Aβ on nicotinic
regulation of inhibitory transmission, we hypothesize
that Aβ might interfere with some downstream signaling
molecule that is differentially involved in the nicotinic
regulation of sIPSC or sEPSC. Our previous studies have
found that PKC activation is often impaired by Aβ treat-
ment [30,32,33], so we examined the involvement of
PKC in nicotinic regulation of sIPSC and sEPSC. PFCslices were pre-incubated with a PKC inhibitor for at
least 1 hour, and sIPSC was recorded in layer V pyram-
idal neurons and sEPSC was recorded in layer I
GABAergic interneurons.
As shown in Figure 7A-C, in PFC pyramidal neurons
treated with the potent and selective PKC inhibitor
GF109203X (1 μM), nicotine failed to cause a significant
increase in the sIPSC amplitude (−3.2 ± 1.7%, n = 7,
Figure 7G), and had a significantly attenuated effect on
sIPSC frequency (18.9 ± 8.7%, n = 7), which was contrary
to the effects of nicotine on sIPSC in control cells
(sIPSC amplitude: 39.4 ± 1.7%; sIPSC frequency: 34.2 ±
7.4%, n = 5). However, nicotine still caused a significant
increase in the sEPSC frequency in GF109203X-treated
interneurons (Figure 7D-F, 97.4 ± 12.6%, n = 8, Figure 7H),
similar to its effect on sEPSC frequency in control cells
(106.1 ± 26.3%, n = 5).
To further confirm the involvement of PKC in nicoti-
nic regulation of synaptic inhibition, we also treated
neurons with a different type of highly specific PKC
nicotine
control
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Figure 6 Aβ did not alter the nicotinic effect on sEPSC in layer I interneurons. A-C, Representative sEPSC traces (A) and cumulative plots of
the distribution of sEPSC amplitude (B) and frequency (C) in the absence (control) or presence of nicotine (5 μM) recorded in a PFC layer I
interneuron. The blockade of sEPSC by DNQX (20 μM) and APV (40 μM) was also shown in A. Scale bars (A): 10pA, 15s. D-F, Representative sEPSC
traces (D) and cumulative plots of the distribution of sEPSC amplitude (E) and frequency (F) in the absence or presence of nicotine recorded in a
PFC layer I interneuron pre-treated with Aβ (1 μM, 3 hours). Scale bars (D): 10pA, 15s. G, Bar plot summary of the percentage change of sEPSC
amplitude and frequency by nicotine in non-treated (−) and Aβ-pretreated layer I interneurons. H, Bar plot summary of the percentage increase
of sEPSC frequency by nicotine in the absence or presence of MEC (10 μM) or MLA (1 μM). *: p < 0.005, ANOVA.
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http://www.molecularneurodegeneration.com/content/8/1/3inhibitor, PKC20-28, which is a peptide containing the
pseudosubstrate sequence from PKC α and PKC β.
N-Terminus is myristoylated to allow membrane per-
meability. As shown in Figure 8, in myr-PKC20-28
(10 μM, 1 hr)-treated neurons, nicotine (5 μM) had
significantly diminished enhancing effect on mIPSCamplitude (control: 44.1 ± 13.6%, n = 4, PKC20-28: 16.5 ±
3.8%, n = 5) and frequency (control: 36.0 ± 7.1%, n = 4,
PKC20-28: 9.9 ± 2.2%, n = 5). These results suggest that
PKC activation is required for nicotinic regulation of


















































































































































































































Figure 7 Inhibiting PKC blocked the nicotinic effect on sIPSC but not sEPSC. A-C, Representative sIPSC recordings (A) and cumulative plots
of the distribution of sIPSC amplitude (B) and frequency (C) in the absence (control) or presence of nicotine (5 μM) recorded in a PFC pyramidal
neuron pretreated with the PKC inhibitor GF109203X (1 μM). Scale bars (A): 100pA, 15s. D-F, Representative sEPSC traces (D) and cumulative plots
of the distribution of sEPSC amplitude (E) and frequency (F) in the absence (control) or presence of nicotine (5 μM) recorded in a PFC layer I
interneuron pretreated with GF109203X (1 μM). Scale bars (D): 10pA, 15s. G, H, Bar plot summary of the percentage change of sIPSC (G) or sEPSC
(H) amplitude and frequency by nicotine in neurons pretreated without (−) or with GF109203X. *: p < 0.05, **: p < 0.01, t-test.





















































































































Figure 8 Highly specific PKC inhibitor blocked the nicotinic effect on sIPSC. A-C, Representative sIPSC traces (A) and cumulative plots of
the distribution of sIPSC amplitude (B) and frequency (C) in the absence (control) or presence of nicotine (5 μM) recorded in a PFC pyramidal
neuron pretreated with myristolated PKC inhibitor 20–28 (10 μM). Scale bars (A): 50 pA, 5 s. D, Bar plot summary of the percentage increase of
sIPSC amplitude and frequency by nicotine in neurons pretreated without (−) or with myr-PKC20-28. *: p < 0.05, t-test.
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Our experiments have shown that, in rat prefrontal cor-
tex, 1) nicotine increased sIPSC in layer V pyramidal
neurons and the firing rate in layer I interneurons, both
of which were disrupted by Aβ; 2) Aβ did not impair
nicotinic regulation of sEPSC in layer I interneurons; 3)
PKC inhibitors differentially interfered with nicotinic
regulation of excitatory or inhibitory transmission, mim-
icking the effect of Aβ. These results suggest that Aβ se-
lectively impairs nicotinic regulation of inhibitory inputs
to cortical pyramidal neurons, which may involve a
PKC-dependent mechanism.
Nicotine often has neuron-specific effects in different
networks, which are mediated by different nAChR sub-
types [21,34,35]. In this study, we have found that nico-
tine enhances both inhibitory inputs to PFC layer V
pyramidal neurons and excitatory inputs to layer I inter-
neurons. In the presence of non-α7 nAChR antagonist
MEC, both sIPSC and sEPSC are irresponsive to nico-
tine, suggesting that α4β2 may mediate these effects of
nicotine [20,36]. Nicotine does not alter the excitability
of layer V pyramidal neurons, but significantly increases
the firing rate of layer I interneurons, an effect mediated
by both α7 and non-α7 nAChRs. Involvement ofdifferent nAChRs may also suggest distinct roles of nico-
tine in regulating neuronal functions. In hippocampal
cultures, α7 and α4β2 displayed distinct patterns of
expression, with α7 preferentially present on the somato-
dendrites whereas α4β2 distributed on both the axonal
and dendritic compartments [37]. Our results are consist-
ent with the finding that presynaptic α4β2 receptors
contribute to neurotransmission [38,39] and both somato-
dendritic α7 and presynaptic α4β2 receptors modulate
neuronal excitability [12,40,41].
Both Aβ accumulation and nicotinic deficits occur in
the progression of AD [42,43]. Aβ peptide may alter nico-
tinic function in several ways. Direct binding of Aβ1–42 to
α7 receptors leads to inhibition of channel open probabil-
ity [44] and ionic current [43,45]. However, several lines of
evidence suggest that direct inhibition of nAChRs by Aβ
might not be enough to explain Aβ-induced impairment
of nicotinic functions. In hippocampal interneurons of
transgenic mice overexpressing Aβ, α7 nAChRs are still
functioning [46]. Aβ is able to elevate presynaptic calcium
levels, which could occlude the enhancing effect of nico-
tine on calcium-dependent transmitter release [47]. Cal-
cium and PKC have been found to be involved in
nicotine-facilitated neurotransmission in interneurons
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similar effect on nicotinic regulation of synaptic transmis-
sion as Aβ, suggesting that PKC could be an important
mediator in Aβ-induced impairment of nAChR functions
in AD. It supports the idea that PKC-related intervention
might be promising for AD treatment [50-52].
In this study, we have found that nicotinic regulation
of interneuron firing and GABAergic inputs to pyram-
idal neurons are selectively susceptible to Aβ, while
nicotinic regulation of excitatory inputs to interneurons
is relatively preserved. It suggests that interneuron-
mediated inhibition and its excitability are Aβ targets. It
is known that inhibitory terminals of fast-spiking inter-
neurons are better equipped to support prolonged trans-
mitter release at a higher frequency in comparison with
pyramidal neurons [53]. Electrical and chemical connec-
tions of cortical interneurons promote their synchronous
firing, thus interneurons play an important role in co-
ordinating cortical activity [54,55], which is critical for
working memory [56]. The Aβ-induced selective im-
pairment of nicotinic regulation of inhibitory inputs to
cortical principal neurons could contribute to the dys-
function of neuronal network and the imbalance of in-




Aβ oligomer was prepared as described previously [28,57].
Nicotine (Sigma), mecamylamine (Sigma), methyllycaconitine
(Tocris), GF109203X (Tocris), myr-PKC20-28 (Calbiochem)
were made freshly from stocks.
Animals
The transgenic mice that coexpress a total of five FAD muta-
tions [APP K670N/M671L (Swedish) + I716V (Florida) +
V717I (London) and PS1 M146L + L286V] [31] was a gener-
ous gift from Dr. William E. Van Nostrand (Stony Brook
University). Transgenic males (Hets) were bred with mature
females (WT). Genotyping were performed by PCR.Slice preparation
All experiments were performed under the supervision of
State University of New York at Buffalo Animal Care
Committee. Sprague Dawley rats (3–5 weeks old) were
anesthetized with 2-bromo-2-chloro-1,1,1-trifluoroethane
(1 ml/100 g) inhalation before decapitation [28,58]. Brains
were quickly removed and sliced (300 μm) with a Leica
(Nussloch, Germany) VP1000S Vibratome. Slices were
then incubated in artificial CSF (in mM: 130 NaCl, 26
NaHCO3, 3 KCl, 5 MgCl2, 1.25 NaH2PO4, 2 CaCl2, and
10 glucose, pH 7.4, 300 mOsm) bubbled with 95% O2 and
5% CO2.Patch clamp recordings
Voltage clamp recording of synaptic currents in slices
was performed as described previously [33,59]. The PFC
slice was placed in a perfusion chamber attached to the
fixed stage of an upright microscope (Olympus Optical,
Melville, NY) and submerged in continuously flowing
ACSF. For sIPSC recording, patch electrode (3–5 MΩ)
was filled with the following solution (in mM): 100 CsCl,
10 HEPES, 1 MgCl2, 1 EGTA, 30N-methyl-d-glucamine
(NMG), 5 MgATP, 0.5 Na2GTP and 12 phosphocreatine,
pH 7.2–7.3, 270–280 mOsm. CNQX or DNQX (20 μM)
and APV (40 μM) were added to ACSF to block AMPA
and NMDA receptors. For sEPSC recording, the internal
solution was composed of (in mM): 130 Cs-methanesul-
fonate, 10 HEPES, 10 CsCl, 4 NaCl, 1 MgCl2, 1 EGTA, 5
NMG, 5 MgATP, and 0.5 Na2GTP and 12 phosphocrea-
tine, pH 7.2, 275–290 mOsm. Bicuculline (10 μM) was
added to ACSF to block GABAA receptors. Cells were
visualized with a 40x water-immersion lens and illumi-
nated with near infrared (IR) light, and the image was
detected with an IR-sensitive CCD camera. A Multi-
clamp 700A amplifier (Axon Instruments) was used for
the recording. Tight seals (2–10 GΩ) from visualized
neurons were obtained by applying negative pressure.
The membrane was disrupted with additional suction,
and the whole-cell configuration was obtained. The ac-
cess resistances were 13–18 MΩ. The membrane poten-
tial was held at −70 mV.
Mini Analysis program (Synaptosoft, Leonia, NJ) was
used to analyze synaptic activity. Individual synaptic
events with fast onset and exponential decay kinetics
were captured with threshold detectors in Mini Analysis
software. All quantitative measurements were taken
4–6 min after drug application. Spontaneous IPSC or
EPSC recordings of 3 min under each condition were
used for obtaining cumulative distribution plots of the
amplitudes and inter-event intervals. To measure cell
excitability, the whole-cell current-clamp technique
[33,59] was used to record spikes evoked by a 500ms de-
polarizing current pulse. The amplitude of injected
current was adjusted so that 5–7 spikes were elicited in
the control ACSF solution. The patch electrode was filled
with an internal solution containing (in mM): 60 K2SO4,
60 NMG, 40 HEPES, 4 MgCl2, 0.5 BAPTA, 12 phospho-
creatine, 2 Na2ATP and 0.2 Na3GTP, pH 7.2–7.3,
265–270 mOsm. The firing rate of each neuron was aver-
aged from 10 consecutive traces under each condition.Data analysis
Statistical comparisons of the synaptic currents were
made using the Kolmogorov-Smirnov (K-S) test. Experi-
ments with two groups were analyzed statistically using
unpaired Student’s t-tests. Experiments with more than
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lowed by post hoc Tukey tests.
Numerical values were expressed as mean ± SEM.
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